Rituximab: an emerging treatment for recurrent diffuse alveolar hemorrhage in systemic lupus erythematosus

Lupus

Volumn 24, Issue 7, 2015, Pages 756-759

  Tse, J R ^a   Schwab, K E ^a   McMahon, M ^a   Simon, Wendy ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

renal lupus; Systemic lupus erythematosus; vasculitis

Indexed keywords

CASPOFUNGIN; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; MEROPENEM; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; MYCOPHENOLIC ACID; PREDNISONE; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; VANCOMYCIN; IMMUNOLOGIC FACTOR;

ADULT; ARTICLE; CASE REPORT; CRACKLE; DIFFUSE ALVEOLAR HEMORRHAGE; DRUG DOSE REDUCTION; DYSPNEA; END STAGE RENAL DISEASE; FEMALE; FIBROSING ALVEOLITIS; HEMOPTYSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; LUNG HEMORRHAGE; LUNG LAVAGE; MIDDLE AGED; PLASMAPHERESIS; PRIORITY JOURNAL; RECURRENT DISEASE; RESPIRATORY DISTRESS; RESPIRATORY FAILURE; SYSTEMIC LUPUS ERYTHEMATOSUS; TACHYPNEA; THORAX PAIN; HEMORRHAGE; LUNG ALVEOLUS; LUNG DISEASES; LUPUS ERYTHEMATOSUS NEPHRITIS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PATHOLOGY; PATHOPHYSIOLOGY; VASCULITIS;

FEMALE; HEMORRHAGE; HUMANS; IMMUNOLOGIC FACTORS; LUNG DISEASES; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MIDDLE AGED; PULMONARY ALVEOLI; RECURRENCE; RITUXIMAB; VASCULITIS;

EID: 84930836241     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203314564235     Document Type: Article

References (12)

1. Todd DJ, Costenbader KH. Dyspnoea in a young woman with active systemic lupus erythematosus. Lupus. 2009 ; 18: 777-784
2. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med. 1991 ; 324: 150-154
3. Narshi CB, Haider S, Ford CM, Isenberg DA, Giles IP. Rituximab as early therapy for pulmonary haemorrhage in systemic lupus erythematosus. Rheumatology. 2010 ; 49: 392-394
4. Pottier V, Pierrot M, Subra JF, et al. Successful rituximab therapy in a lupus patient with diffuse alveolar haemorrhage. Lupus. 2011 ; 20: 656-659
5. Gillis JZ, Dall'era M, Gross A, Yazdany J, Davis J. Six refractory lupus patients treated with rituximab: A case series. Arthritis Rheum. 2007 ; 57: 538-542
6. Nellessen CM, Pöge U, Brensing KA, Sauerbruch T, Klehr HU, Rabe C. Diffuse alveolar haemorrhage in a systemic lupus erythematosus patient successfully treated with rituximab: A case report. Nephrol Dial Transplant. 2008 ; 23: 385-386
7. Pinto LF, Candia L, Garcia P, et al. Effective treatment of refractory pulmonary hemorrhage with monoclonal anti-CD20 antibody (rituximab). Respiration. 2009 ; 78: 106-109
8. Scheiman Elazary A, Klahr PP, Hershko AY, Dranitzki Z, Rubinow A, Naparstek Y. Rituximab induces resolution of recurrent diffuse alveolar hemorrhage in a patient with primary antiphospholipid antibody syndrome. Lupus. 2012 ; 21: 438-440
9. Gonzalez-Echavarri C, Pernas B, Ugarte A, Ruiz-Irastorza G. Severe multiorganic flare of systemic lupus erythematosus successfully treated with rituximab and cyclophosphamide avoiding high doses of prednisone. Lupus. 2014 ; 23: 323-326
10. García-Carrasco M, Jiménez-Hernández M, Escárcega RO, et al. Use of rituximab in patients with systemic lupus erythematosus: An update. Autoimmun Rev. 2009 ; 8: 343-348
11. Green RJ, Ruoss SJ, Kraft SA, Duncan SR, Berry GJ, Raffin TA. Pulmonary capillaritis and alveolar hemorrhage. Update on diagnosis and management. Chest. 1996 ; 110: 1305-1316
12. Ramos-Casals M, Soto MJ, Cuadrado MJ, Khamashta MA. Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases. Lupus. 2009 ; 18: 767-776